Learn how immunotherapies harness a person’s immune system to fight diseases
Learn more about Aduro’s clinical programs
Download the 2018 Annual Report
June 02, 2019 Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas
Are you interested in working for a company where interactions are authentic, commitment is high and people excel together?